This weeks' content is a detailed summary of a Harvard Business case study on the microbiome testing company 'DayTwo'. Instead of the usual 15-25+ page case studies we send out, our team took the time to read all of it and provide you with only the most important details!
What is DayTwo all about?
DayTwo, the leader in precision nutrition with the world’s most advanced proprietary microbiome science, offers a sustainable path to remission for metabolic diseases (diabetes, prediabetes, and clinical obesity). Metabolic disease is the first condition to be addressed by DayTwo’s microbiome discovery platform.
The company’s solution includes gut microbiome profiling, artificial intelligence to predict blood sugar response to foods, and dedicated virtual care. The company’s results set a new national benchmark for diabetes and metabolic disease care -- with significant sustained clinical results in reducing A1C, improving Time in Range, and reducing or eliminating prescription medications. DayTwo’s scientific research is cited by the National Institutes of Health as a foundational element in its 10 year, $150 million strategic plan for precision nutrition.
In this case study we take a look at what DayTwo had to consider when introducing its product to the consumer market such as choosing a business model, finding the right audience, competitive landscape and entering the American market.